Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 19th Annual Medicinal & Pharmaceutical Sciences Congress Hong Kong.

Submit your Abstract
or e-mail to

vikashrathod@conferenceseries.com
medpharma@worldpharmasummit.com
medpharma@worldpharmasummit.com

Scientific Program Day 1

Day :

  • Pharmacotherapy|Nanotechnology|Biopharmaceutics|Pharmacovigilance| Drug Development|Toxicology

Session Introduction

Jeremy Choo

Republic Polytechnic, Singapore

Title: Design, develop and evaluate dispensary software in RP-KTPH teaching dispensary
Speaker
Biography:

Jeremy Choo has completed his Bachelor of Science (Honors) from University of Melbourne and Master of Pharmacy from Murdoch University. After graduation, he tutored and demonstrated various aspects of biomedical sciences including pharmacology to both local and overseas tertiary institutions Anderson Junior College, Temasek Polytechnic, Singapore and also Institute of Science, Raffles Education Corporation and Edith Cowan University in Perth. He was certified nationally by WSQ to be Curriculum Developer, Trainer and Assessor, Leadership and People Management, as well as having professional knowledge in medication management review, Australia and ambulatory care, smoking cessation, counseling, Singapore as well as anticoagulation studies (USA).

Abstract:

Introduction & Aim: Recent pedagogical approaches within the field of applied sciences incorporate problem-based learning and hands-on training. Republic Polytechnic’s School of Applied Sciences (SAS), in collaboration with the School of Engineering and the School of Infocomm, has developed RPMED, a user-friendly and efficient dispensing software as a learning platform to hone student’s clinical and dispensing skills. By embracing new technologies and automation such as RPMED, students will be inculcated with the values and principles of pharmaceutical care such as medication safety, patient care continuum, dispensing process efficiencies and documentation procedures.
 
Method: Developing RPMED requires a system of IT improvements. First, the students review current dispensing software issues raised by previous development teams. Next, students from SAS address these issues in collaboration with teams from the School of Infocomm. The third phase involves enhancing and implementing new features in RPMED. Lastly, end users feedback surveys are prepared, designed, conducted and reviewed by SAS students to determine RPMED software usability and future enhancements.
 
Result: Three improvement processes within RPMED had been identified and implemented: a barcode system, a drug interaction matrix and drug imaging. Implementing barcode systems on pharmaceutical products reduces medication selection errors, thereby improving dispensing accuracy and efficiency. A drug interaction matrix improves medication safety by allowing concurrent checks for drug interactions when new medications are added to patients’ drug chart. A pop-up alert will appear when drug interactions are found. Drug imaging incorporates reference images within the software for quick and accurate identification and selection of medicines. End users feedback surveys showed widespread acceptance and usability among students.
 
Conclusion: Developing and using RPMED allows students to appreciate the verisimilitudes with commercially available dispensing software. The system of checks and balances within RPMED allow students to gain insight into the complexities involved in IT use within pharmaceutical care.

Tariq Dennison

GFM Asset Management, Hong Kong

Title: A Fund Manager’s Investment Outlook on the Biotechnology and Pharmaceutical Sectors
Speaker
Biography:

Tariq Dennison CFPCM manages retirement plan investment portfolios at his own firm GFM Asset Management, a Hong Kong licensed asset manager and US registered investment advisor. Mr. Dennison is the author of the book “Invest Outside the Box: Understanding Different Asset Classes and Strategies”, and puts this into practice by investing client accounts in portfolios of stocks, bonds, and ETFs the same way he invests his own money. Tariq has worked at Commerzbank, Bear Stearns, JP Morgan, CIBC, and Society General in New York, Toronto, London and Hong Kong, and also teaches fixed income and alternative assets at ESSEC Business School in Singapore and for CFA Singapore. Mr. Dennison holds a Masters in Financial Engineering degree from the University of California at Berkeley’s Haas School of Business. Tariq is one of the few Hong Kong based specialists in US pension funds, including IRA, 401(k), and defined benefit plans

Abstract:

Statement of the Problem: Biotechnology and pharmaceutical stocks have significantly outperformed broader equity benchmarks over the past 10 years, but these companies remain uniquely difficult to value and risk manages, even for professional investors. Fund Manager Tariq Dennison presents a financial outlook of stocks in the biotechnology and pharmaceutical sectors, starting with a top-down look at how broad and industry focused funds and ETFs choose to invest in these sectors, using examples from actual funds. Next, a few examples of financial models of select companies are highlighted to show some of the challenges and opportunities in valuing shares of companies focused on different stages of drug development. Research and early development stage companies are more often valued and risk managed using a “real options” model, while later stage companies with mature cash flows may be valued with classic “discounted cash flow” models. These top-down and bottom up views are then combined to pave an outlook for investing in funds and shares in the bio & pharma space, and what factors might change fund managers’ views. Valuation is a key emphasis of this presentation and main difference between a practitioner and investor in technologies, since it is easy to lose money investing in even the best technologies if the price paid is too high.

Ashraf H Abadi

German University in Cairo, Egypt

Title: Modulation of the estrogenic/antiestrogenic properties of the anticancer drug Tamoxifen
Speaker
Biography:

Ashraf Abadi has completed his PhD from the College of Pharmacy, University of Florida, USA and Cairo University. He is the head of Pharmaceutical Chemsitry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo and former Dean of the Faculty. He has published more than 80 papers in reputed journals and 7 patents and has been serving as an editorial board member and reviewer of reputed international pharmaceutical sciences journals. He supervised more than 6- Master and Ph.D. theses in the field of Drug Discovery and Pharmaceutical Chemistry

Abstract:

Tamoxifen is Selective Estrogen Receptor Modulator (SERM) that is widely used as an adjunctive endocrine therapy for the treatment of postmenopausal women with hormone-dependent breast cancer, metastatic breast cancer and reduction of breast cancer incidence in high risk women. Its anticancer effect is attributed to its anti-estrogenic properties. Nevertheless, Tamoxifen has estrogen-like effects in the uterus, this results in a spectrum of abnormalities involving the genital tract, the
most significant being an increased incidence of endometrial cancer and uterine sarcoma. That is why its therapeutic use is limited to 5-10 years duration. This modulation in the functional activity is attributed to the ligand-dependent receptor conformational changes, differential interactions with numerous Co-Activators (CoA) and Co-Repressors (CoR) expressed and recruited in different tissues and subsequent changes in gene transcription. Most of literature linked the anti-estrogenic properties of Tamoxifen to the presence of the substituted aminoethyloxy side chain that introduces a conformational change in helix 12 of the ER-alpha receptors, blocking the co-activator binding. Moreover, in the body Tamoxifen is metabolized to the more potent anti-estrogenic hydroxyltamoxifen and endoxifen that contributed to its anti-cancer effects. In this report, two series of Tamoxifen analogues were designed and synthesized, both of them are with substituted aminoethyloxy side chain but one of them is with oxygenated substituent and the other one is with a chlorine atom on position 4 of ring C. The latter substitution blocks the 4-hydroxylation, preventing the formation of the oxygenated derivative. Interestingly, all the compounds with the oxygenated side chain were found to be anti-estrogenic in the Yeast Estrogen Screening (YES) assays and to be potent anticancer, while all the chlorine derivatives were found to be estrogenic and devoid of the anticancer activity. This indicates that the functional activity of such Tamoxifen analogues is mainly a function of its ability to be hydroxylated on position 4 of ring C. This represents a new concept to explain the SERM properties of Tamoxifen and its analogues. Such intriguing results are supported by literature review showing that the expression of CYP2D6 is higher in breast tissues rather than uterine tissues.

Pravin Kumar

Atopic Dermatitis: Etiology and Treatment, India

Title: Atopic Dermatitis: Etiology and Treatment
Speaker
Biography:

Mr. Pravin Kumar is presently working as Associate Professor in Department of Pharmaceutics, Laureate Institute of Pharmacy, Kangra, Himachal Pradesh, India. Completed his post- graduation in 2008 from JSS College of Pharmacy, Mysore, India and currently pursuing his Ph.D from Uttarakhand Technical University, Dehradun, India. Pharmaceutical researcher and teacher with Master in Pharmacy (Industrial Pharmacy) and Bachelor in Pharmacy, degree in pharmaceutical sciences with more than 10 years of total experience. Guided more than 15 post graduate students in pharmaceutical sciences related research. Basic focused area in research is about the herbal excipients and drugs in pharmaceutical sciences. Presently, doing research on the development of topical formulation of herbal drugs for the long-term management of atopic dermatitis. More than 16 internationals research and review publications with total impact factor of 5.012.   Participated as speaker and research delegate in more than 10 international and national conferences.

Abstract:

Atopic Dermatitis: Etiology and Treatment

  • Poster

Session Introduction

Karina Grzanka

Poznan University of Medical Sciences, Poland

Title: The system of tolfenamic acid with cyclodextrins and their identification
Speaker
Biography:

Karina Grzanka is a student of the fifth year of Pharmacy at the Poznań University of Medical Sciences. She has been actively working in the Herba Student Research Group in the area of searching for possibilities of using cyclodextrin inclusion complexes. In particular with regard to the possibility of modifying the release of the active substance from the prepared complex. She has also the skills and experience necessary to work on the study of permeability through the system of biological membranes and the rate of dissolution

Abstract:

Introduction & Objective: Tolfenamic acid is a Non-Steroidal Anti-Inflammatory Drug (NSAID) with antipyretic, analgesic and anti-inflammatory effects. Its action is mainly based on the inhibition of COX-1 and COX-2. It is effecative in treating the pain associated with the acute attack of migraines in adults. The drug is absorbed slowly by oral administration. The oral absorption is delayed and it gives a mean lag-time to absorption of 32 minutes. Tolfenamic acid is slightly soluble in water, buffer pH=6.8 and 0.1 M hydrochloric acid
 
Method: To increase the solubility, tolfenamic acid was connected with magnesium stearate in a ratio of 1:1. An alkaline environment was created that allowed the tolfenamic acid to be dissolved in the buffer pH=6.8. Inclusion cyclodextrin systems (methyl-β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin) were prepared in solid phase using co-precipitation method. Technique involves stirring together equimolar methanol solution of mixture of tolfenamic acid and magnesium stearate and water cyclodextrin solution. Identification of cyclodextrin tolfenamic acid complex was based on changes FT-IR (Fourier Transform-Infrared Spectroscopy), XRPD (X-ray Powder Diffraction) and DSC (Differential Scanning Calorimetry). The system of tolfenamic acid and cyclodextrin was dissolved in a buffer pH=6.8 imitating the digestive environment in intestines. The studies of apparent solubility were conducted by using Paddle Drug Dissolution Apparatus.
 
Results: Apparent solubility study showed that tolfenamic acid in system with methyl-β-CD after 190 minutes was solvated in 86%, while system with 2-hydroxypropylo-beta-cyclodextrin after 190 minutes was solvated in 91%. The tolfenamic acid in free form was dissolved in 62.5%. The results were evaluated significantly.
 
Conclusion: These studies showed that the combination of the tolfenamic acid with cyclodextrin alters its dissolution rate. The tolfenamic acid-cyclodextrin systems showed better solubility in compared to the free form. The type of cyclodextrin used to obtain the tolfenamic acid was a significant importance.

The studies were supported by Ministry of Science and Higher Education from project “ Best of The Best 3.0”

Delfina Hanus

Poznań University of Medical Sciences, Poland

Title: Preparation of Piroxicam-2-hydroxypropyl-α-cyclodextrin system and studies of solubility changes of Piroxicam
Speaker
Biography:

Delfina Hanus is a student of the fifth year of pharmacy at the Poznań University of Medical Sciences. She is a Member of the Scientific Academic Circle Herba and conducts research on the possibilities of modifying the release rate of Piroxicam from complexes obtained by co-precipitation. She has knowledge and experience in the scope of planned tasks to be implemented in these areas of the project.

Abstract:

Introduction & Aim: Piroxicam is a non-steroidal and anti-inflammatory drug. The effect of this drug is based on prevention of the prostaglandin production via. inhibition of cyclooxygenase. This drug is indicated for treatment of rheumatoid osteoarthritis, postoperative pain. The drug is absorbed slowly and gradually by oral and rectal administration
 
Method: Piroxicam is poorly soluble in water and in biological fluids at physiological pH values. Systems of cyclodextrin and Piroxicam were prepared in solid state using the co-precipitation method. The procedure requires stirring together methanol solution of Piroxicam and water solution of cyclodextrin in different ratios: 1:1 and 1:2. The identification of cyclodetrinpiroxicam systems was based on changes on FT-IR spectra as well as DSC diffractograms. The changes of solubility of Piroxicam after its incorporation into CD were examined using paddle apparatus in 0,1M HCl, medium simulating conditions in stomach. Sample solutions collected from dissolution testing were measured by UV spectroscopy to observe the changes of solubility of the Piroxicam.
 
Results: Apparent solubility studies showed that Piroxicam in cyclodextrin system in ratio 1:1 after 165 minutes was solvated in 85% and in ratio 1:2 in 69% while the Piroxicam in free form was solvated in 62%. Similarity factors f1 for the first study was 0,4232 while difference factor f2 was 0,0205 and for the second f1 was 0,1507 and f2 was 0,5772.
 
Conclusion: Systems of cyclodextrin with Piroxicam in ratio 1:1 increased solubility of investigated molecule. Statistical evaluation proves that two apparent solubility curves are significantly different. The other inclusion system also increased solubility of Piroxicam and values of f1 and f2 proves that two apparent solubility curves are slightly different. According to apparent solubility study, same concentration of the Piroxicam is reached faster when it is systems with CDs.